Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Nike’s Aggressive Holiday Discounting Signals Major Strategy Shift Under New CEO

by Team Lumida
December 19, 2024
in Health and Longevity
Reading Time: 3 mins read
A A
0
person holding iPhone taking picture on Nike label

Photo by Kristian Egelund on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com
• Nike expected to report third consecutive quarterly sales decline (9% year-over-year)
• Company offering unprecedented 30% discounts across product lines
• New CEO prioritizing inventory clearance and retail partnership expansion
• Strategy affecting retail partners’ margins and brand perception

What Happened?

Nike has launched an aggressive discounting campaign under new CEO Elliott Hill, offering up to 30% off most footwear products during the crucial holiday shopping season. The company is selling products on its website at significantly lower prices than retail partners, with some popular models like the Dunk sneakers available for $85 compared to $115 at traditional retailers. This marks a significant shift from the company’s previous direct-to-consumer focus, with Nike now rekindling relationships with retailers it had previously cut ties with, including DSW and Academy Sports.

Why It Matters?

This strategic pivot represents a crucial moment in Nike’s business model evolution. The aggressive discounting reflects the urgency to address inventory challenges while potentially risking brand value and retail partnerships. The strategy has already impacted major retail partners’ results, with companies like Foot Locker reporting weaker quarterly sales. The shift also indicates a departure from the previous administration’s direct-to-consumer focus, suggesting a more balanced distribution approach. This comes at a critical time when Nike faces increased competition in key categories like running, where brands like Brooks and Hoka have gained market share.

What’s Next?

The market will closely watch Nike’s quarterly earnings report for insights into the effectiveness of this strategy. Key focus areas include inventory levels, gross margin impact, and guidance for future quarters. The success of new product launches, particularly the Alphafly 3 in the running category, will be crucial for recovery. Additional challenges include potential new tariffs under the incoming Trump administration and ongoing European customs disputes. The company’s ability to balance inventory clearance with brand protection, while managing retail partner relationships, will be critical for long-term success. Investors will particularly focus on Hill’s long-term strategy presentation and plans for developing new blockbuster products to replace aging franchises.

Previous Post

Chinese Local Government Vehicles Set Record in Offshore Yuan Bond Sales Amid Domestic Restrictions

Next Post

Trump’s Intervention Derails Bipartisan Funding Bill, Raising Shutdown Risk

Recommended For You

U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge

by Team Lumida
15 hours ago
U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge

Key takeaways Powered by lumidawealth.com U.S. life expectancy rose to 79 years in 2024, the highest on record, up 0.6 years YoY Drug-overdose deaths fell more than 26%, the...

Read more

Longevity Hacks Go Data-Driven as Preventive Health Becomes a Scalable Growth Market

by Team Lumida
2 days ago
man running on road near grass field

Key takeaways Powered by lumidawealth.com Longevity is shifting from wellness trends to measurable, science-backed health optimization Simple behaviors like strength training, protein intake, sleep consistency, and fasting windows show...

Read more

Preventive Health and Aging Tech Emerge as the Next Major Growth Market

by Team Lumida
3 days ago
black and red cherries on white bowl

Key takeaways Powered by lumidawealth.com Longevity is moving from niche wellness to a core healthcare and investment theme, powered by aging demographics and tech-driven prevention Breakthroughs in early diagnostics,...

Read more

Cancer Survivors Face Growing Risk of Heart Damage from Life-Saving Treatments

by Team Lumida
7 days ago
Cancer Survivors Face Growing Risk of Heart Damage from Life-Saving Treatments

Key Takeaways Powered by lumidawealth.com Advances in cancer treatments are leading to more survivors, but many face delayed heart damage from therapies. Modern treatments like immune checkpoint inhibitors and...

Read more

Sleep Regularity Is the Longevity Edge Most People Ignore

by Team Lumida
1 week ago
woman sleeping on bed under blankets

Key takeaways Powered by lumidawealth.com Sleep regularity (same bedtime/wake time) often matters as much as total hours for metabolic and cardiovascular health. Big swings in sleep timing can impair...

Read more

Longevity Moves From Lifestyle Trend to Investable Theme as Aging Demographics Drive Demand

by Team Lumida
1 week ago
diagram

Key takeaways Powered by lumidawealth.com Aging demographics are accelerating demand for therapies and services that extend healthspan, not just lifespan. Capital is shifting from reactive care to prevention, chronic-disease...

Read more

Metformin: The “Longevity Drug” With Big Promise—and Unfinished Proof

by Team Lumida
1 week ago
Metformin: The “Longevity Drug” With Big Promise—and Unfinished Proof

Key takeaways Powered by lumidawealth.com Metformin is a low-cost, widely prescribed diabetes drug being studied for whether it can delay age-related disease beyond glucose control. The core debate: strong...

Read more

Rapamycin: The “Most-Proven-in-Mice” Longevity Drug Still Searching for Human Proof

by Team Lumida
2 weeks ago
Rapamycin: The “Most-Proven-in-Mice” Longevity Drug Still Searching for Human Proof

Key takeaways Powered by lumidawealth.com Rapamycin (sirolimus) has some of the strongest preclinical longevity evidence, but human data is still early and fragmented. The core investment challenge is translation...

Read more

GLP-1s Are Becoming the First “Longevity Drug” With Real-World Outcomes Data

by Team Lumida
2 weeks ago
GLP-1s Are Becoming the First “Longevity Drug” With Real-World Outcomes Data

Key takeaways Powered by lumidawealth.com GLP-1 drugs are shifting from “weight-loss meds” to risk-reduction platforms, with evidence supporting meaningful improvements in cardiometabolic outcomes in obese/overweight populations. The investable story...

Read more

Wearable Health Devices: Helpful or Harmful to Our Well-Being?

by Team Lumida
3 weeks ago
Wearable Health Devices: Helpful or Harmful to Our Well-Being?

Key Takeaways: Powered by lumidawealth.com Wearable devices like the Oura Ring and Apple Watch have become essential tools for tracking health metrics such as sleep and heart rate. While...

Read more
Next Post
Donald Trump beside man in black suit

Trump's Intervention Derails Bipartisan Funding Bill, Raising Shutdown Risk

SouthState’s $2B Independent Bank Acquisition Advances, Signals M&A Revival

SouthState's $2B Independent Bank Acquisition Advances, Signals M&A Revival

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

IPO Dreams Dashed: Bank of America Under Investigation

IPO Dreams Dashed: Bank of America Under Investigation

October 10, 2024
LA Palisades Fire Sparks Real Estate Rush Amidst Devastation

LA Palisades Fire Sparks Real Estate Rush Amidst Devastation

February 11, 2025
a close up of a clock with different colored numbers

Treasury Yields Rise Amid Uncertainty on Fed’s Interest Rate Path

February 18, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018